Zymeworks IncCommon Stock is a biotechnology business based in the US. Zymeworks IncCommon Stock shares (ZYME) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.96 – an increase of 3.1% over the previous week. Zymeworks IncCommon Stock employs 280 staff and has a trailing 12-month revenue of around $76.3 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.96 |
|---|---|
| 52-week range | $8.21 - $17.70 |
| 50-day moving average | $12.22 |
| 200-day moving average | $12.87 |
| Wall St. target price | $21.35 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.96 from 2025-05-02
| 1 week (2025-04-25) | 3.10% |
|---|---|
| 1 month (2025-04-04) | 18.36% |
| 3 months (2025-02-04) | -8.99% |
| 6 months (2024-11-04) | -12.20% |
| 1 year (2024-05-03) | 40.87% |
|---|---|
| 2 years (2023-05-03) | 53.37% |
| 3 years (2022-05-03) | 81.26% |
| 5 years (2020-05-04) | 35.59 |
| Revenue TTM | $76.3 million |
|---|---|
| Gross profit TTM | $-60,195,000 |
| Return on assets TTM | -14.57% |
| Return on equity TTM | -30.54% |
| Profit margin | -160.8% |
| Book value | $4.91 |
| Market Capitalization | $901.7 million |
TTM: trailing 12 months
We're not expecting Zymeworks IncCommon Stock to pay a dividend over the next 12 months.
Over the last 12 months, Zymeworks IncCommon Stock's shares have ranged in value from as little as $8.21 up to $17.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zymeworks IncCommon Stock's is 1.174. This would suggest that Zymeworks IncCommon Stock's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zymeworks Inc. , a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .